Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells

BACKGROUND: Ibrutinib is a Bruton’s tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK) inhibitor used for treating chronic lymphocytic leukaemia (CLL) and other cancers. Although ibrutinib is known to inhibit the growth of breast cancer cell growth in vitro, its impact on the treatment a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Cancer
Hlavní autoři: Varikuti, Sanjay, Singh, Bhawana, Volpedo, Greta, Ahirwar, Dinesh K., Jha, Bijay K., Saljoughian, Noushin, Viana, Agostinho G., Verma, Chaitenya, Hamza, Omar, Halsey, Gregory, Holcomb, Erin A., Maryala, Ritvik J., Oghumu, Steve, Ganju, Ramesh K., Satoskar, Abhay R.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7109110/
https://ncbi.nlm.nih.gov/pubmed/32025027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0743-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky